AQR Capital Management
EGRX

AQR Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AQR Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-374,992
Closed -$1.4M – 2997
2024
Q3 		$1.4M Sell
374,992
-321,805
-46% -$1.54M ﹤0.01% 1677
2024
Q2 		$3.9M Sell
696,797
-182,276
-21% -$794K 0.01% 1129
2024
Q1 		$4.61M Buy
879,073
+385,408
+78% +$2.12M 0.01% 1014
2023
Q4 		$2.58M Buy
493,665
+210,707
+74% +$2.08M ﹤0.01% 1234
2023
Q3 		$4.46M Sell
282,958
-85,015
-23% -$1.53M 0.01% 972
2023
Q2 		$7.15M Buy
367,973
+102,553
+39% +$2.43M 0.02% 763
2023
Q1 		$7.53M Buy
265,420
+130,105
+96% +$3.86M 0.02% 742
2022
Q4 		$3.96M Buy
135,315
+39,400
+41% +$1.25M 0.01% 992
2022
Q3 		$2.53M Buy
95,915
+44,599
+87% +$1.64M 0.01% 1105
2022
Q2 		$2.28M Buy
51,316
+9,353
+22% +$430K 0.01% 1050
2022
Q1 		$2.08M Sell
41,963
-5,262
-11% -$253K ﹤0.01% 1153
2021
Q4 		$2.4M Sell
47,225
-209
-0.4% -$10.8K ﹤0.01% 1070
2021
Q3 		$2.65M Sell
47,434
-8,273
-15% -$407K ﹤0.01% 1004
2021
Q2 		$2.38M Sell
55,707
-5,702
-9% -$235K ﹤0.01% 1130
2021
Q1 		$2.56M Buy
61,409
+16,724
+37% +$777K ﹤0.01% 1082
2020
Q4 		$2.08M Sell
44,685
-20,814
-32% -$973K ﹤0.01% 1156
2020
Q3 		$2.78M Sell
65,499
-26,700
-29% -$1.17M ﹤0.01% 972
2020
Q2 		$4.42M Sell
92,199
-52,418
-36% -$2.62M 0.01% 834
2020
Q1 		$6.65M Buy
144,617
+17,121
+13% +$859K 0.01% 718
2019
Q4 		$7.66M Buy
127,496
+14,195
+13% +$847K 0.01% 829
2019
Q3 		$6.41M Sell
113,301
-1,105
-1% -$62.1K 0.01% 894
2019
Q2 		$6.37M Buy
114,406
+6,452
+6% +$337K 0.01% 897
2019
Q1 		$5.45M Buy
107,954
+10,519
+11% +$468K 0.01% 952
2018
Q4 		$3.93M Buy
97,435
+29,091
+43% +$1.5M ﹤0.01% 1020
2018
Q3 		$4.74M Buy
68,344
+20,549
+43% +$1.56M ﹤0.01% 1026
2018
Q2 		$3.62M Sell
47,795
-16,595
-26% -$1.04M ﹤0.01% 1163
2018
Q1 		$3.39M Sell
64,390
-94,479
-59% -$5.49M ﹤0.01% 1145
2017
Q4 		$8.49M Sell
158,869
-41,765
-21% -$2.32M 0.01% 836
2017
Q3 		$12M Buy
200,634
+90,997
+83% +$5.5M 0.01% 723
2017
Q2 		$8.65M Buy
109,637
+75,090
+217% +$6.14M 0.01% 821
2017
Q1 		$2.87M Buy
34,547
+14,743
+74% +$1.1M ﹤0.01% 1228
2016
Q4 		$1.57M Sell
19,804
-71
-0.4% -$5.16K ﹤0.01% 1518
2016
Q3 		$1.39M Sell
19,875
-11,024
-36% -$611K ﹤0.01% 1585
2016
Q2 		$1.2M Sell
30,899
-4,577
-13% -$191K ﹤0.01% 1541
2016
Q1 		$1.44M Buy
35,476
+7,879
+29% +$500K ﹤0.01% 1426
2015
Q4 		$2.45M Sell
27,597
-16,937
-38% -$1.34M ﹤0.01% 1154
2015
Q3 		$3.3M Buy
44,534
+17,162
+63% +$1.43M 0.01% 932
2015
Q2 		$2.21M Buy
27,372
+18,872
+222% +$1.23M ﹤0.01% 1143
2015
Q1 		$356K Buy
+8,500
New +$241K ﹤0.01% 1818

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AQR Capital Management's EGRX Position: Q4 2024 in Review

AQR Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 374,992 shares — an estimated $1.4M sold.

AQR Capital Management first reported a position in EGRX in Q1 2015 and held it in 39 quarters. The position peaked at $12M in Q3 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • AQR Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • AQR Capital Management sold 374,992 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $1.4M.
  • AQR Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 39 quarters.
  • AQR Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $12M in Q3 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on AQR Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.